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Table S1
Correlation of gene expression with the artesunate IC50s determined in the cell lines UKF-NB-3, UKF-NB-3rVCR10, UKF-NB-3rCDDP1000, UKF-NB-6,
UKF-NB-6rVCR10, and UKF-NB-6rCDDP1000 as indicated by Kendall's t-test.
Gene expression was determined by gene microarray analysis using Human Genome Survey Microarray V2.0 chips. Experiments were performed in triplicate.
Genes were selected from: Biochem Pharmacol 2002;64:617-23; Mol Pharmacol 2003;64:382-94; In Vivo 2005;19:225-32, Pharmacogenomics J 2006;6:269-78.
Genes that significantly (fdr < 0.05) correlate in their expression with artesunate IC50s are marked in bold.
correlation = direction of correlation between gene expression and artesunate IC50 as indicated by Kendall's t-test; (-) means inverse, (+) means positive
Ref_ART_correlation = direction of correlation as indicated in the literature
fdr_BF = false discovery rate determined using the Method of Bonferroni
p_greater = p-value for positive correlation
p_less = p-value for inverse correlation
tau = value for the extent of correlation (values can range from -1 to +1)
Table S1 all genes_1
Probe_ID Gene_Symbol Gene_NameRef_ART_correlation correlation p_value p_greater p_less tau
210662 ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1(-) (+) 0,360 0,360 0,765 0,200
210249 ANAPC5 anaphase promoting complex subunit 5(-) (-) 0,136 0,932 0,136 -0,467
100039 ANAPC7 anaphase promoting complex subunit 7(-) (-) 0,500 0,640 0,500 -0,067
217383 ANG angiogenin, ribonuclease, RNase A family, 5|ribonuclease, RNase A family, 4(-) (-) 0,235 0,864 0,235 -0,333
115827 AXL AXL receptor tyrosine kinase(+) (+) 0,360 0,360 0,765 0,200
200907 BAG1 BCL2-associated athanogene(-) (-) 0,136 0,932 0,136 -0,467
122149 BAG3 BCL2-associated athanogene 3(+) (-) 0,500 0,640 0,500 -0,067
118877 BMP1 bone morphogenetic protein 1(-) (+) 0,008 0,008 0,999 0,867
186957 BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase)(+) (+) 0,360 0,360 0,765 0,200
158227 BRAF v-raf murine sarcoma viral oncogene homolog B1(-) (-) 0,028 0,992 0,028 -0,733
119580 BRCA2 breast cancer 2, early onset(-) (+) 0,500 0,500 0,640 0,067
211100 CAT catalase (-) (+) 0,068 0,068 0,972 0,600
199852 CCNL1 cyclin L1 (-) (-) 0,068 0,972 0,068 -0,600
171254 CDC25A cell division cycle 25A(-) (-) 0,500 0,640 0,500 -0,067
104054 CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3(+) (+) 0,136 0,136 0,932 0,467
711223 CDC42SE1 CDC42 small effector 1(+) (+) 0,136 0,136 0,932 0,467
188843 CDK8 cyclin-dependent kinase 8(-) (-) 0,068 0,972 0,068 -0,600
191305 CDKN3 cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)(-) (-) 0,500 0,640 0,500 -0,067
101377 CIDEB cell death-inducing DFFA-like effector b|leukotriene B4 receptor 2(-) (-) 0,235 0,864 0,235 -0,333
141012 COL18A1 collagen, type XVIII, alpha 1(+) (-) 0,235 0,864 0,235 -0,333
105493 COL1A2 collagen, type I, alpha 2(+) (+) 0,500 0,500 0,640 0,067
111306 COL4A2 collagen, type IV, alpha 2(+) (+) 0,360 0,360 0,765 0,200
111068 CSF1 colony stimulating factor 1 (macrophage)(+) (-) 0,360 0,765 0,360 -0,200
204583 CSK c-src tyrosine kinase (-) (-) 0,235 0,864 0,235 -0,333
154907 CTGF connective tissue growth factor(+) (-) 0,068 0,972 0,068 -0,600
128477 CXCL13 chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant)(+) (-) 0,068 0,972 0,068 -0,600
166020 CYR61 cysteine-rich, angiogenic inducer, 61(+) (+) 0,235 0,235 0,864 0,333
132884 DHDH dihydrodiol dehydrogenase (dimeric)(+) (+) 0,235 0,235 0,864 0,333
184324 DNASE2 deoxyribonuclease II, lysosomal(+) (+) 0,360 0,360 0,765 0,200
192173 DVL3 dishevelled, dsh homolog 3 (Drosophila)(+) (+) 0,008 0,008 0,999 0,867
101210 EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1(+) (+) 0,136 0,136 0,932 0,467
136952 EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)(+) (-) 0,500 0,640 0,500 -0,067
198606 EMP1 epithelial membrane protein 1(+) (-) 0,500 0,640 0,500 -0,067
196671 EphA2 EPH receptor A2 (+) (+/-) 0,500 0,500 0,500 0,000
185249 ERCC5 excision rep (-) (-) 0,235 0,864 0,235 -0,333
204787 F3 coagulation factor III (thromboplastin, tissue factor)(+) (+) 0,235 0,235 0,864 0,333
176815 FEN1 flap structure-specific endonuclease 1(-) (+) 0,235 0,235 0,864 0,333
113042 FGF2 fibroblast growth factor 2 (basic)(+) (-) 0,136 0,932 0,136 -0,467
136386 FN1 fibronectin 1 (-) (-) 0,136 0,932 0,136 -0,467
105390 FOSB FBJ murine osteosarcoma viral oncogene homolog B(+) (+) 0,136 0,136 0,932 0,467
117028 FOSL2 FOS-like antigen 2 (+) (-) 0,136 0,932 0,136 -0,467
196828 GCLC glutamate-cysteine ligase, catalytic subunit(+) (+) 0,235 0,235 0,864 0,333
145632 GCLM glutamate-cysteine ligase, modifier subunit(+) (-) 0,500 0,640 0,500 -0,067
202429 GJA4 gap junction protein, alpha 4, 37kDa (connexin 37)(+) (-) 0,360 0,765 0,360 -0,200
100777 GSPT1 G1 to S phase transition 1(-) (-) 0,008 0,999 0,008 -0,867
562311 GSTA1 glutathione S-transferase A1(+) (-) 0,235 0,864 0,235 -0,333
170684 GSTA2 glutathione S-transferase A2(+) (-) 0,235 0,864 0,235 -0,333
135910 GSTM4 glutathione S-transferase M4ot available (-) 0,360 0,765 0,360 -0,200
214807 GSTP1 glutathione S-transferase pi(+) (+) 0,360 0,360 0,765 0,200
133590 GSTT2 glutathione S-transferase theta 2(+) (-) 0,500 0,640 0,500 -0,067
158330 GSTZ1 glutathione transferase zeta 1 (maleylacetoacetate isomerase)not available (+) 0,235 0,235 0,864 0,333
138789 HIF1A hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)(+) (+) 0,500 0,500 0,640 0,067
103694 HMGB1 high-mobility group box 1(-) (-) 0,500 0,640 0,500 -0,067
171265 HMGN2 high-mobility group nucleosomal binding domain 2(+) (-) 0,360 0,765 0,360 -0,200
137986 IL13RA1 interleukin 13 receptor, alpha 1(+) (-) 0,360 0,765 0,360 -0,200
115545 IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor)(+) (-) 0,360 0,765 0,360 -0,200
187921 IRF4 interferon regulatory factor 4(-) (+) 0,008 0,008 0,999 0,867
111199 KIF5B kinesin family member 5B(+) (+) 0,360 0,360 0,765 0,200
180804 LIG1 ligase I, DNA, ATP-dependent(-) (-) 0,500 0,640 0,500 -0,067
176287 MADD MAP-kinase activating death domain(-) (+) 0,235 0,235 0,864 0,333
131781 MEN1 multiple endocrine neoplasia I(-) (+) 0,028 0,028 0,992 0,733
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137942 MGST1 microsomal glutathione S-transferase 1(+) (+) 0,500 0,500 0,640 0,067
177655 MGST3 microsomal glutathione S-transferase 3(+) (+) 0,235 0,235 0,864 0,333
135420 MMP11 matrix metallopeptidase 11 (stromelysin 3)(+) (+ 0,360 0,360 0,765 0,200
112640 MMP9 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)(-) (+) 0,360 0,360 0,765 0,200
161318 MPDZ multiple PDZ domain protein(+) (-) 0,360 0,765 0,360 -0,200
110763 MPHOSPH10 M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein)(-) (-) 0,500 0,640 0,500 -0,067
217047 MPHOSPH6 M-phase phosphoprotein 6(-) (-) 0,500 0,640 0,500 -0,067
200184 MYB v-myb myeloblastosis viral oncogene homolog (avian)(-) (-) 0,136 0,932 0,136 -0,467
132666 MYC v-myc myelocytomatosis viral oncogene homolog (avian)(-) (+/-) 0,500 0,500 0,500 0,000
108491 NID2 nidogen 2 (osteonidogen)(+) (+) 0,068 0,068 0,972 0,600
124833 NOS2A nitric oxide synthase 2A (inducible, hepatocytes)(-) (+) 0,235 0,235 0,864 0,333
106462 NRCAM neuronal cell adhesion molecule(+) (-) 0,500 0,640 0,500 -0,067
130678 PA2G4 proliferation-associated 2G4, 38kDa(-) (-) 0,136 0,932 0,136 -0,467
218609 PDCD2 programmed cell death 2(-) (+/-) 0,500 0,500 0,500 0,000
208672 PLAU plasminogen activator, urokinase(+) (+) 0,028 0,028 0,992 0,733
158513 PRDX2 peroxiredoxin 2 not available (-) 0,136 0,932 0,136 -0,467
215425 PRDX6 peroxiredoxin 6 not available (+) 0,500 0,500 0,640 0,067
190571 RAB2 RAB2, member RAS oncogene family(+) (+) 0,360 0,360 0,765 0,200
140316 RAN RAN, member RAS oncogene family(-) (+) 0,360 0,360 0,765 0,200
199683 RHOC ras homolog gene family, member C(+) (+) 0,235 0,235 0,864 0,333
129829 RND3 Rho family GTPase 3(+) (+) 0,360 0,360 0,765 0,200
215633 RPS3 ribosomal protein S3 (-) (+/-) 0,500 0,500 0,500 0,000
144600 TFPI2 tissue factor pathway inhibitor 2(+) (+) 0,500 0,500 0,640 0,067
158090 TGFB2 transforming growth factor, beta 2(+) (-) 0,360 0,765 0,360 -0,200
162911 THBS1 thrombospondin 1 (+) (-) 0,500 0,640 0,500 -0,067
179728 TOP1 topoisomerase (DNA) I(+) (+) 0,500 0,500 0,640 0,067
116930 TOP2B topoisomerase (DNA) II beta 180kDanot available (-) 0,235 0,864 0,235 -0,333
164267 TUBB4 tubulin, beta 4 (+) (-) 0,235 0,864 0,235 -0,333
164857 TXNRD1 thioredoxin reductase 1(+) (-) 0,136 0,932 0,136 -0,467
136294 TXNRD2 thioredoxin reductase 2(+) (+) 0,136 0,136 0,932 0,467
193721 UBE2A ubiquitin-conjugating enzyme E2A (RAD6 homolog)(+) (+) 0,008 0,008 0,999 0,867
204651 UNG uracil-DNA glycosylase(-) (-) 0,235 0,864 0,235 -0,333
170337 VEGFC vascular endothelial growth factor C(+) (+) 0,360 0,360 0,765 0,200
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Probe_ID Gene_SymbolGene_NameRef_ART_correlationco relation p_value p_greater p_less tau
118877 BMP1 bone morphogenetic protein 1(-) (+) 0,008 0,008 0,999 0,867
158227 BRAF v-raf murine sarcoma viral oncogene homolog B1(-) (-) 0,028 0,992 0,028 -0,733
192173 DVL3 dishevelled, dsh homolog 3 (Drosophila)(+) (+) 0,008 0,008 0,999 0,867
100777 GSPT1 G1 to S phase transition 1(-) (-) 0,008 0,999 0,008 -0,867
187921 IRF4 interferon regulatory factor 4(-) (+) 0,008 0,008 0,999 0,867
131781 MEN1 multiple endocrine neoplasia I(-) (+) 0,028 0,028 0,992 0,733
208672 PLAU plasminogen activator, urokinase(+) (+) 0,028 0,028 0,992 0,733
193721 UBE2A ubiquitin-conjugating enzyme E2A (RAD6 homolog)(+) (+) 0,008 0,008 0,999 0,867
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